Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Organization

Fujian Cancer Hospital

40 clinical trials

22 abstracts

Abstract
Randomized phase 3 study of first-line AZD3759 (zorifertinib) versus gefitinib or erlotinib in EGFR-mutant (EGFRm+) non–small-cell lung cancer (NSCLC) with central nervous system (CNS) metastasis.
Org: Guangdong Lung Cancer Institute, China National Biotec Group, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Guangzhou JOYO Pharma, Cancer Hospital,
Clinical trial
Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 Vs Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer: Randomized Control, Open, Multicenter Trial-2 (TAOS-3B-Trial-2)
Status: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
Prospective Single-arm, Exploratory, Multicenter Phase II Clinical Study of Camrelizumab Combined With Chemoradiotherapy in the Treatment of Advanced First-line Esophageal Phosphorous Carcinoma
Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
PD-1 Antibody(Tislelizumab) Plus Irinotecan Combined With POF in Treatment Naive Advanced Gastric Cancer: A Phase II Study.
Status: Not yet recruiting, Estimated PCD: 2024-04-11
Clinical trial
Clinical Observation of Trolamine Retention Enema in Preventing Acute Radiation-induced Rectal Injury: a Real-world Multicenter Prospective Study
Status: Recruiting, Estimated PCD: 2025-05-01
Clinical trial
A Phase II, Prospective, Multicenter Study of Cadonilimab in Combination With FOLFOXIRI and Bevacizumab as First Line Therapy for Metastatic MSS Colorectal Cancer.
Status: Recruiting, Estimated PCD: 2024-03-01
Abstract
First-in-class PD-1/IL-2 bispecific antibody fusion protein IBI363 in patients with advanced melanoma: Safety and efficacy results from a phase I study.
Org: Fujian Cancer Hospital, First Chest Radiotherapy Department, Hunan Cancer Hospital, Changsha, China, Hunan Cancer Hospital/the Affiliated Cancer Hospital of Xiangya School of Medicine, Changsha, China, Department of Melanoma Oncology, The Third People's Hospital of Zhengzhou, Zhengzhou, China, The Third People's Hospital of Zhengzhou,
Abstract
Genomic characteristics of tumour necrosis in lung squamous cell carcinoma.
Org: Fujian Cancer Hospital, Hunan Cancer Hospital/the Affiliated Cancer Hospital of Xiangya School of Medicine, Changsha, China, Department I of Thoracic Oncology, Peking University Cancer Hospital and Institute, Beijing, China, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Peking University Cancer Hospital and Institute (Beijing Cancer Hospital), Beijing, China,
Abstract
Sintilimab and anlotinib combination therapy in PD-L1-positive recurrent/metastatic cervical carcinoma: A 3-year follow-up of ALTER-C201 study.
Org: Fujian Provincial Cancer Hospital, Fuzhou, Fujian, China, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital,
Abstract
Single-cell landscape of the immune microenvironment of leptomeningeal metastases in non-small cell lung cancer treated with pemetrexed sheath injection.
Org: Fujian Cancer Hospital, Fuzhou University, Fujian Shengdi Pharmaceutical, China National Biotec Group,
Abstract
A single-arm phase II study of platinum doublet induction chemotherapy combined with toripalimab for driver gene-negative advanced NSCLC.
Org: Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, Clinical Oncology School of Fujian Medical University,
Clinical trial
Metronomic Oral Vinorelbine Combination With Tislelizumab in EGFR/ALK-negative Advanced NSCLC Patients Intolerant to First-line Standard Chemotherapy: A Singlearm Phase Il Clinical Trial
Status: , Estimated PCD: 2025-02-07
Clinical trial
Phase I/II Study of the Combination of Irinotecan and POF (Paclitaxel Plus Oxaliplatin Plus 5-fluorouracil Plus Leucovorin) and Tislelizumab
Status: Recruiting, Estimated PCD: 2023-12-31
Abstract
Clinical significance of the risk model based on exosome-derived miRNA and miR-486-5p for endometrial cancer.
Org: Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital,
Abstract
Neoadjuvant pamiparib in patients with newly diagnosed advanced ovarian cancer: A single-arm, prospective phase II trial.
Org: Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy, Department of Gynecology, Puyang Oilfield General Hospital, Puyang, China, Department of Gynecologic Oncology, Gynecology and Obstetrics Center, The First Hospital of Jilin University, Changchun, China,
Clinical trial
Study on the Efficacy, Safety and Cost-effectiveness of Cadonilimab in the Treatment of Cervical Cancer
Status: Not yet recruiting, Estimated PCD: 2026-12-01
Abstract
A multicenter, single-arm, open-label phase II study to evaluate the efficacy and safety of YH003 in combination with pembrolizumab and nab-paclitaxel in the first-line treatment of patients with unresectable/metastatic mucosal melanoma.
Org: Fujian Cancer Hospital, Sun Yat-sen University Cancer Center Gansu Hospital, West China Hospital, Union Hospital, Hunan Cancer Hospital/the Affiliated Cancer Hospital of Xiangya School of Medicine, Changsha, China,
Abstract
Predictive value of C reactive protein (CRP) and D-dimer in patients with advanced cervical cancer treated with sintilimab and anlotinib.
Org: Department of Gynecology, Puyang Oilfield General Hospital, Puyang, China, Fujian Medical University Cancer Hospital, Fujian Cancer Hospital, Clinical Oncology School of Fujian Medical University, Fuzhou University,
Clinical trial
A Phase II Multicenter Clinical Study of Improved Short-course Radiotherapy Combined With CAPOX and PD-1 Monoclonal Antibody for Locally Advanced Mid-low Rectal Cancer
Status: Not yet recruiting, Estimated PCD: 2025-12-01
Clinical trial
Prospective Randomized Trial Comparing Induction Chemotherapy and Immunotherapy Combined Radiotherapy With or Without Concurrent Chemotherapy for Stage III-IVa Nasopharyngeal Carcinoma
Status: Not yet recruiting, Estimated PCD: 2025-01-01
Clinical trial
Aumolertinib as First-line Treatment in EGFR-Mutant Pulmonary Adenosquamous Carcinoma: A Multicenter, Single-Arm, Prospective Study (ARISE)
Status: Recruiting, Estimated PCD: 2023-12-31
Clinical trial
Clinical Study of Adbelizumab Combined With Concurrent Chemoradiotherapy in Locally Advanced Cervical Cancer
Status: Not yet recruiting, Estimated PCD: 2028-02-01
Clinical trial
The Correlation Between Homologous Recombination Deficiency Detection and the Efficacy of PARP Inhibitors in Ovarian Cancer
Status: Not yet recruiting, Estimated PCD: 2026-05-01
Clinical trial
Phase Ib/II Clinical Study of PARP Inhibitor CVL218 in Combination With Therapy in Patients With Advanced Solid Tumors
Status: Not yet recruiting, Estimated PCD: 2026-06-01
Clinical trial
A Study to Evaluate the Effects of Radiotherapy Combined With Tyrosine Kinase Inhibitor (TKI) and Anti-PD-1 Antibody for Stage IIIA Hepatocellular Carcinoma With Portal Vein Tumor Thrombus(PVTT)
Status: Recruiting, Estimated PCD: 2024-07-30
Clinical trial
Oncorine (H101) Combined With Tislelizumab and Platinum-based Two-drug Chemotherapy in Previously Untreated Advanced Non-small Cell Lung Cancer, a Phase II Single-arm Clinical Trail
Status: Recruiting, Estimated PCD: 2024-05-09
Clinical trial
The Efficacy and Safety of Tislelizumab Combined With Anlotinib and S1 Plus Oxaliplatin as Neoadjuvant Therapy for the Locally Advanced Adenocarcinoma of Esophagogastric Junction : a Prospective，Single-arm, Phase II Trial (TASTE Trial)
Status: Not yet recruiting, Estimated PCD: 2025-08-31
Clinical trial
A Single-arm, Exploratory Study of Adebrelimab Combined With Fuzuloparib in the Treatment of Patients With Recurrent Platinum-resistant Ovarian Cancer
Status: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
A Single-arm, Sequential Study Assessing the Efficacy and Safety of SMET12 and Toripalimab Combined Chemotherapy in Patients With EGFR Positive Advanced Non-small Cell Lung Cancer (NSCLC) : First-line Treatment or Failed From First-line Immune Checkpoint Inhibitor Treatment.
Status: Not yet recruiting, Estimated PCD: 2024-10-20
Clinical trial
Efficacy and Safety of Cadonilimab (AK104) Plus Chemotherapy in the Treatment of Recurrent or Advanced Endometrial Cancer: a Multicenter, Prospective Phase II Trial
Status: Not yet recruiting, Estimated PCD: 2025-10-31
Clinical trial
Stop and go Strategy as First-line Treatment in Patients With Objective Response After Systematic Chemotherapy for Widely de Novo Metastatic Nasopharyngeal Carcinoma: A Phase II Trial
Status: Not yet recruiting, Estimated PCD: 2026-05-01
Clinical trial
Double Dose of Third-generation EGFR-TKI Plus Intrathecal Pemetrexed Versus Double Dose of Third-generation EGFR-TKI in NSCLC Patients With Leptomeningeal Progression Following the Treatment of Routine Dose of Third-generation EGFR-TKI: a Phase II Randomized, Multicenter Study
Status: Not yet recruiting, Estimated PCD: 2028-04-01
Clinical trial
A Phase II Clinical Study of the Efficacy and Safety of Tislelizumab Combined With Fruquintinib and Chidamide in the Treatment of Unresectable or Advanced Microsatellite Stabilized (MSS/pMMR) Colorectal Cancer With Liver Metastases
Status: Not yet recruiting, Estimated PCD: 2025-12-01
Clinical trial
PD-1 Monoclonal Antibody With Recombinant Human Adenovirus Type 5 Injection for the Treatment of Advanced Malignant Melanoma Patients Who Has Failed Immunotherapy: an Exploratory Single-arm Study
Status: , Estimated PCD: 2023-08-01
Clinical trial
An Open, Single-arm, Multicenter Phase Ib Clinical Study of XH-30002 Capsule Combined With Afatinib Tablets for the Treatment of Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma
Status: Not yet recruiting, Estimated PCD: 2025-06-01
Clinical trial
Neoadjuvant Chemoradiotherapy Combined With Tislelizumab in the Treatment of Locally Advanced Rectal Cancer--Randomized, Open, Multicenter Clinical Study
Status: Not yet recruiting, Estimated PCD: 2025-06-01
Clinical trial
Surufatinib Combined With Serplulimab Plus Carboplatin and Etoposide as First-line Treatment for Extensive-stage Small-cell Lung Cancer：a Multicenter, Open-label, Phase I/II Trial
Status: Not yet recruiting, Estimated PCD: 2025-06-01
Clinical trial
Health-related Quality of Life of Patients With Locally Advanced Thyroid Cancer Receiving Targeted Therapy
Status: Recruiting, Estimated PCD: 2025-01-31
Clinical trial
Observation of Oxaliplatin Hypersensitivity and Neurotoxicity in GI Tract, and Reuse of Oxaliplatin Hypersensitivity in Gastrointestinal Tumors: A Prospective, Open-Label, Multicenter, Phase II Study
Status: Not yet recruiting, Estimated PCD: 2025-09-01
Clinical trial
A Phase 2, Multi-Center, Single Arm Study to Evaluate Lenvatinib Plus Tislelizumab for Locally Advanced Unresectable or Metastatic Hepatocellular Carcinoma With Hepatitis B Virus Infection and Biomarker Analyses
Status: Not yet recruiting, Estimated PCD: 2025-06-01
Clinical trial
Efficacy and Safety of SBRT Followed by Tislelizumab Plus Cetuximab and Irinotecan in Patients With Previously Treated RAS Wild-type Advanced Refractory Colorectal Cancer: a Phase II, Single-arm Study
Status: Not yet recruiting, Estimated PCD: 2024-04-05
Clinical trial
A Prospective, Single-arm Study on the Efficacy and Safety of Recombinant Human Adenovirus Type 5 Injection Combined With PD-1 Monoclonal Antibody and Nab-paclitaxel in the Treatment of Patients With Liver Metastases From Malignant Melanoma
Status: Not yet recruiting, Estimated PCD: 2024-12-01
Clinical trial
Efficacy and Safety of Eribulin-Based Regimen in the Treatment of Metastatic Triple-Negative Breast Cancer and Comparison With Other Chemotherapy Regimen: A Single-Center Retrospective Study
Status: Active (not recruiting), Estimated PCD: 2023-08-01
Clinical trial
A Single Arm, Exploratory Clinical Study on the Neoadjuvant Treatment of Neuroendocrine Cervix Carcinoma With Camrelizumab Combined With Etoposide and Cisplatin
Status: Recruiting, Estimated PCD: 2026-08-31
Abstract
Efficacy and safety of tunlametinib in patients with advanced NRAS-mutant melanoma: A multicenter, open-label, single-arm, phase 2 study.
Org: Peking University Cancer Hospital & Institute, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, The Third People's Hospital of Zhengzhou, Cancer Hospital of the University of Chinese Academy of Sciences, Hangzhou, China,
Abstract
Transarterial chemoembolization combined with lenvatinib and camrelizumab for unresectable hepatocellular carcinoma: A prospective, single-arm, multicenter study.
Org: The First Affiliated Hospital of Fujian Medical University, Fujian Provincial Hospital, Zhangzhou Hospital Affiliated to Fujian Medical University, Xiamen Hospital of Traditional Chinese Medicine, Mengchao Hepatobiliary Hospital of Fujian Medical University,
Abstract
A phase 2 study of HLX07 as monotherapy or combination therapy in patients with locally advanced, unresectable, or metastatic esophageal squamous cell carcinoma.
Org: National Cancer Center Hospital East, Kashiwa, Japan, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, Anyang Tumor Hospital, Hunan Cancer Hospital/the Affiliated Cancer Hospital of Xiangya School of Medicine, Changsha, China,
Abstract
First-in-human dose escalation and expansion study of SYSA1801, an antibody-drug conjugate targeting claudin 18.2 in patients with resistant/refractory solid tumors.
Org: Fujian Cancer Hospital, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, The Affiliated Tumor Hospital of Harbin Medical University, Medical Oncology Department of Gastrointestinal Cancer, Liaoning Cancer Hospital & Institute, Cancer Hospital of China Medical University, Shenyang, China,
Abstract
Final overall survival analysis of JUPITER-02: A phase 3 study of toripalimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC).
Org: Sun Yat-sen University Cancer Center Gansu Hospital, The Affiliated Cancer Hospital of Guangzhou Medical University, Fudan University Cancer Center, Cancer Center Union Hospital Tongji Medical College Huazhong University of Science and Technology, Affiliated Hospital of Guangdong Medical University,
Abstract
Effect of machine learning-based integration develops M2 macrophage-activation genes signature on outcomes in nasopharyngeal carcinoma.
Org: Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital,
Abstract
Long-term survival outcomes and immune checkpoint inhibitor (ICI) retreatment in patients with advanced cervical cancer who received camrelizumab plus apatinib in the CLAP study.
Org: Sun Yat-sen University Cancer Center Gansu Hospital, Sun Yat-sen Memorial Hospital of SunYat-sen University, Guangzhou, China, The First Affiliated Hospital of Sun Yat-sen University, Jiangsu Hengrui Pharmaceuticals Co., Ltd., Clinical Oncology School of Fujian Medical University,
Abstract
Cerebrospinal fluid circulating tumor DNA for the detection and characterization of leptomeningeal metastasis in non-small cell lung cancer.
Org: Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Department of Thoracic Oncology, NHO Kyushu Cancer Center, Fukuoka, Japan, Fujian Medical University Cancer Hospital, Fujian Cancer Hospital and Fujian Medical University Cancer Hospital,
Abstract
Effect of intrathecal pemetrexed on survival in patients with lung adenocarcinoma with leptomeningeal metastasis: A propensity score matching analysis..
Org: Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Department of Thoracic Oncology, NHO Kyushu Cancer Center, Fukuoka, Japan, Fujian Medical University Cancer Hospital,
Abstract
Lactate metabolism as a dictator of patient outcomes and immune microenvironment in head and neck squamous carcinoma.
Org: Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital,
Abstract
Penpulimab plus platinum-based chemotherapy combined with anlotinib in first-line treatment for persistent, recurrent, or metastatic cervical cancer: A single-arm, open-label phase Ⅱ study (ALTN-AK105-II-06).
Org: Department of Gynecology, Puyang Oilfield General Hospital, Puyang, China, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China,
Abstract
Prognosis-related molecular subtyping of nasopharyngeal carcinoma.
Org: Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital,
Clinical trial
Nituzumab Plus Serplulimab Combined With SBRT in Recurrent Advanced Cervical Cancer: A Prospective, Multicenter, Single-arm, Phase II Clinical Trial
Status: Recruiting, Estimated PCD: 2025-01-31
Clinical trial
Efficacy and Safety of AK104 Combined With Pemetrexed, Carboplatin and Recombinant Human Adenovirus 5 Injection in Advanced Recurrent Cervical Cancer: a Multicenter, Single-arm, Prospective Phase II Clinical Study
Status: Recruiting, Estimated PCD: 2025-10-10
Clinical trial
A Study of Sintilimab Combined With Chemotherapy for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma
Status: Recruiting, Estimated PCD: 2025-03-19
Clinical trial
Phase II Study of Different Doses of Radiotherapy Combined With Sintilimab in the Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma
Status: Not yet recruiting, Estimated PCD: 2026-06-01
Clinical trial
Short-course Radiotherapy Combined With Sintilimab for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma
Status: Not yet recruiting, Estimated PCD: 2025-06-01
Clinical trial
Chemotherapy Plus EGFR Monoclonal Antibody in Patients With Liver Metastases From Colorectal Cancer With ctDNA Superselective Negative Genes：a Phase II Single-arm Study
Status: Not yet recruiting, Estimated PCD: 2025-06-30